Evidence map›Paper›PMID 30716424›Full record

ArticleNeuroscience letters2019

Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype.

John Parker, Tahseen Mozaffar, Ashlynn Messmore, Joshua L Deignan, Virginia E Kimonis, John M Ringman

Open access · greenAbstract readCase Reports
In one paragraph

Article in Neuroscience letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. The curious case of a heterozygous loss-of-functionMolecular neurodegeneration advances · 2025
    Article
  4. Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene.International journal of molecular sciences · 2022
    Review
  5. Article
  6. Frontiers in aging neuroscience · 2022
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

John ParkerDepartment of Neurology, Keck School of Medicine at USC, United States; Department of Neurology, University of California, Irvine, United States.
Tahseen MozaffarDepartment of Neurology, University of California, Irvine, United States.
Ashlynn MessmoreDepartment of Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine, United States.
Joshua L DeignanUCLA Molecular Diagnostics Laboratories, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, United States.
Virginia E KimonisDepartment of Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine, United States.
John M RingmanDepartment of Neurology, Keck School of Medicine at USC, United States. Electronic address: John.ringman@med.usc.edu.
University of California, Irvine · USKeck Hospital of USC · US

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRASKIE, MEREDITH NICOLE · 1985 to 2019
$41.0M
UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 2000 to 2019
$37.0M
The structural and functional connectome across Alzheimer's disease subtypesU01AG051218 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RINGMAN, JOHN M · 2015 to 2018
$3.6M
NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG016573NIA NIH HHS U01 AG051218
6 · The paper itself

Abstract

objectiveWe report a 35 year-old male with childhood learning disability and early onset dementia who is homozygous for the A431E variant in the PSEN1 gene. Presenilin1 mutations are associated with autosomal dominant Alzheimer's dementia with young and somewhat stereotyped onset. Such variants may cause Alzheimer's dementia through aberrant processing of amyloid precursor protein through effects on γ-secretase activity. γ-secretase is involved in the cleavage of many proteins critical to normal function, including brain development. Therefore, manifestations in persons without normal Presenilin1 function is of interest.

methodsClinical evaluation including family history, examination, brain MRI, and genetic analysis.

resultsOur patient had mild developmental delay, chronic nighttime behavioral disturbance, and onset of progressive cognitive deficits at age 33. Clinical evaluation demonstrated spastic paraparesis and pseudobulbar affect. Brain MRI revealed cerebral atrophy disproportionate to age. Chronic microhemorrhages within bilateral occipital, temporal, and right frontal lobes were seen. Sanger sequencing confirmed homozygosity for the A431E variant in PSEN1, which is a known pathogenic variant causing autosomal dominant Alzheimer's dementia.

conclusionsOur report demonstrates that homozygosity for pathogenic Presenilin1 variants is compatible with life, though may cause a more aggressive phenotype with younger age of onset and possibly REM behavior disorder.

Indexed as

HomozygoteAdultAlzheimer DiseaseGenetic Predisposition to DiseaseHumansMaleMutationPhenotypePresenilin-1Presenilin-1PSEN1 protein, humanA431EAlzheimer’s diseaseAutosomal dominantHomozygotePSEN1REM behavior disorderSpastic paraparesis

Identifiers

PMID30716424
PMCPMC7759143
OpenAlexW2911306567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.